Seeking Alpha

Johnson & Johnson (JNJ)

  • Jun. 4, 2012, 8:58 AM
    Dendreon (DNDN) -8.6% premarket after data from Johnson & Johnson (JNJ) and Medivation (MDVN) at the ASCO conference increases competitive pressure for DNDN's Provenge cancer drug. Patients taking JNJ's Zytiga in a late-stage pre-chemo prostate cancer study lived 27.2 months vs. 21.7 months for Provenge.
    | Comment!
  • Jun. 3, 2012, 3:17 AM
    Drug companies have been presenting trial data at the American Society of Clinical Oncology meeting in Chicago. Showing good results are J&J's (JNJ) Zytiga for prostate cancer, Roche's (RHHBY.PK) T-DM1 and Avastin for breast and ovarian tumors respectively, Teva's (TEVA) Treanda for the immune system, and Bristol Myers' (BMY) BMS-936558 for lung, kidney and skin cancer.
  • May. 31, 2012, 5:48 PM
    For what it's worth, Goldman analyst Jami Rubin thinks Johnson & Johnson (JNJ) would be more valuable if it split up than as one conglomerate: "On an operational basis, we believe that JNJ’s businesses, separated as independent companies, would benefit from being more focused and potentially achieve peer group performance levels or better."
  • May. 31, 2012, 11:14 AM
    Johnson & Johnson (JNJ) files for FDA marketing approval of its Type 2 diabetes pill canagliflozin, which is one of J&J's most promising drug candidates. (PR)
    | Comment!
  • May. 30, 2012, 7:43 PM
    Some of the old-line technical indicators are beginning to show signs of breaking down, meaning it's time to high-tail it to the sidelines, says Dennis Gartman. Time-tested models like Dow Theory - where the Dow Transports failed to make new highs when the Industrials did - are pointing to a sell off and warning its time to make an exit. If you must buy, however, Gartman recommends looking at coal, shipping stocks or high dividend yielders like GE and Johnson & Johnson (JNJ). (video).
  • May. 25, 2012, 8:58 AM
    At the top of Goldman Sachs' VIP List of 50 stocks most important to hedge funds is Apple (AAPL), followed by GOOG, ESRX, MSFT, QCOM, C, GM, PCLN, JPM and LMCA. Leading the list of the firm's top 50 short positions is JNJ, XOM, INTC, IBM, AMZN, T, CVX, VZ, DUK and DIS.
  • May. 23, 2012, 5:38 PM
    An FDA advisory panel recommends against approval of Johnson & Johnson's (JNJ) Xarelto blood thinner to reduce life-threatening blood clots. JNJ already markets the pill to treat irregular heartbeat and patients undergoing hip or knee replacement surgery.
    | Comment!
  • May. 21, 2012, 8:59 AM
    J&J's (JNJ +0.2%) blood thinner Xarelto seems to cut the risk of new heart attacks and strokes in people with cardiac problems, the FDA says in a review, although missing data raises doubts that the treatment actually works. An FDA advisory panel is due to vote on Wednesday on whether to recommend the drug.
    | 1 Comment
  • May. 17, 2012, 11:05 AM
    GSK, J&J (JNJ) and Amgen (AMGN) yesterday released positive results from small trials of cancer drugs ahead of a big industry meeting in early June. GSK combined two melanoma medicines, JNJ's already approve Zytiga helped eliminate prostate cancer that hadn't yet spread, and Amgen has revived the once discarded rilotumumab for treating gastric cancer.
    | Comment!
  • May. 15, 2012, 1:50 PM
    Johnson & Johnson's (JNJ +0.5%) subsidiary Alza Corp. and Janssen Pharmaceutica NV agree to transfer world-wide rights for the premature ejaculation treatment Priligy to drug developer Furiex Pharmaceuticals (FURX +9.3%).
    | Comment!
  • May. 9, 2012, 11:34 AM
    J&J (JNJ) adds another approval request to the FDA for Xarelto, applying to use the blood thinner for helping to reduce the risk of blood clots developing in heart stents in patients with acute coronary syndrome. Xarelto is already authorized for certain use cases.
    | Comment!
  • May. 1, 2012, 11:49 AM
    New J&J (JNJ) CEO Alex Gorsky is looking to strengthen the company's medical-device unit via takeovers, he tells Bloomberg in an interview. "We remain committed to cardiovascular," Gorsky says, despite sales shrinking 44% since 2006. On the analyst wish list are Edwards Lifesciences (EW) and St. Jude Medical (STJ).
  • Apr. 30, 2012, 5:20 AM
    Pure pharmaceuticals players, like AstraZeneca (AZN), Bristol-Myers (BMY) and Eli Lilly (LLY), are likely to face higher earnings pressure over the next three years than more-diversified firms like J&J (JNJ) or Bayer (BAYRY.PK), says Fitch. Cash-rich pure-players with a relatively weak R&D pipeline, like AZN, may be tempted to go on buying sprees.
    | Comment!
  • Apr. 26, 2012, 10:58 AM
    Johnson & Johnson (JNJ +0.4%) announces at its annual shareholders meeting a 7.0% increase in its quarterly dividend rate, from $0.57 per share to $0.61 per share.
  • Apr. 19, 2012, 5:12 AM
    The EU approves Johnson & Johnson's (JNJ) $21.3B purchase of Swiss medical device maker Synthes after J&J pledged to divest its trauma operations in the region. "We obtained remedies to ensure that competition will remain strong in these markets," EU Competition Commissioner Joaquin Almunia says.
    | Comment!
  • Apr. 17, 2012, 8:12 AM
    More on Johnson & Johnson's (JNJ) Q1: Worldwide Consumer sales -2.4% Y/Y to $3.6B, hurt by negative currency impact of 2.9%. Worldwide pharmaceutical sales +1.2% to $6.1B, led by strong international sales of Remicade. Worldwide Medical Devices and Diagnostics sales -0.3% to $6.4B. Sees FY12 EPS of $5.07-$5.17, above prior guidance of $5.05-$5.15. Shares +0.5% premarket. (PR)
    | 1 Comment
Visit Seeking Alpha's
JNJ vs. ETF Alternatives
Company Description
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale ofproducts in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.